To evaluate the effectiveness of patisiran in patients with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation.

Inclusion Criteria:

• Diagnosed with ATTRv amyloidosis with polyneuropathy, with a documented V122I or T60A mutation

• PND score of I-IIIB at baseline.

• Exposure to commercial patisiran in one of the 3 cohorts:

  • Prospective Cohort: Naive to patisiran treatment at the time of enrollment with intention to initiate treatment with patisiran.
  • Mixed cohort: Currently on commercial patisiran therapy for less than 12 months at study enrollment.
  • Retrospective cohort: Exposed to commercial patisiran treatment for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.

Exclusion Criteria:

• New York Heart Association (NYHA) heart failure classification ≥3
• Karnofsky Performance Status (KPS) <60%
• Unstable congestive heart failure (CHF)
• Known primary amyloidosis (AL) or leptomeningeal amyloidosis
• Prior major organ transplant
• Previously received patisiran
• Previous treatment with a TTR silencing therapy

Participants with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation